nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—UGT1A9—Mycophenolic acid—systemic scleroderma	0.26	0.321	CbGbCtD
Canagliflozin—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.145	0.179	CbGbCtD
Canagliflozin—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0722	0.0893	CbGbCtD
Canagliflozin—ALB—Captopril—systemic scleroderma	0.0572	0.0707	CbGbCtD
Canagliflozin—ALB—Mycophenolate mofetil—systemic scleroderma	0.045	0.0556	CbGbCtD
Canagliflozin—ABCB1—Lisinopril—systemic scleroderma	0.0399	0.0494	CbGbCtD
Canagliflozin—ALB—Prednisone—systemic scleroderma	0.036	0.0445	CbGbCtD
Canagliflozin—ABCB1—Captopril—systemic scleroderma	0.0299	0.037	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—systemic scleroderma	0.029	0.0358	CbGbCtD
Canagliflozin—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0235	0.0291	CbGbCtD
Canagliflozin—ABCB1—Prednisone—systemic scleroderma	0.0188	0.0233	CbGbCtD
Canagliflozin—ALB—Methotrexate—systemic scleroderma	0.018	0.0223	CbGbCtD
Canagliflozin—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0141	0.0174	CbGbCtD
Canagliflozin—CYP3A4—Prednisone—systemic scleroderma	0.0113	0.0139	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—systemic scleroderma	0.00944	0.0117	CbGbCtD
Canagliflozin—Pancreatitis—Azathioprine—systemic scleroderma	0.000688	0.0036	CcSEcCtD
Canagliflozin—Blood creatinine increased—Mycophenolic acid—systemic scleroderma	0.000685	0.00359	CcSEcCtD
Canagliflozin—Dehydration—Mycophenolic acid—systemic scleroderma	0.00068	0.00356	CcSEcCtD
Canagliflozin—Angioedema—Pentoxifylline—systemic scleroderma	0.000675	0.00354	CcSEcCtD
Canagliflozin—Hypoglycaemia—Lisinopril—systemic scleroderma	0.000675	0.00353	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Mycophenolic acid—systemic scleroderma	0.000668	0.0035	CcSEcCtD
Canagliflozin—Diabetes mellitus—Mycophenolate mofetil—systemic scleroderma	0.000663	0.00347	CcSEcCtD
Canagliflozin—Breast disorder—Mycophenolic acid—systemic scleroderma	0.000661	0.00346	CcSEcCtD
Canagliflozin—Pancreatitis—Leflunomide—systemic scleroderma	0.00065	0.0034	CcSEcCtD
Canagliflozin—Convulsion—Pentoxifylline—systemic scleroderma	0.00064	0.00335	CcSEcCtD
Canagliflozin—Renal failure acute—Mycophenolate mofetil—systemic scleroderma	0.000625	0.00327	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.000625	0.00327	CcSEcCtD
Canagliflozin—Pancreatitis—Mycophenolic acid—systemic scleroderma	0.00062	0.00324	CcSEcCtD
Canagliflozin—Blood creatinine increased—Lisinopril—systemic scleroderma	0.000617	0.00323	CcSEcCtD
Canagliflozin—Dry mouth—Pentoxifylline—systemic scleroderma	0.000615	0.00322	CcSEcCtD
Canagliflozin—Dehydration—Lisinopril—systemic scleroderma	0.000613	0.00321	CcSEcCtD
Canagliflozin—Pollakiuria—Leflunomide—systemic scleroderma	0.000612	0.0032	CcSEcCtD
Canagliflozin—Thirst—Mycophenolate mofetil—systemic scleroderma	0.000606	0.00318	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Lisinopril—systemic scleroderma	0.000602	0.00315	CcSEcCtD
Canagliflozin—Infection—Pentoxifylline—systemic scleroderma	0.000599	0.00314	CcSEcCtD
Canagliflozin—Breast disorder—Lisinopril—systemic scleroderma	0.000595	0.00312	CcSEcCtD
Canagliflozin—Shock—Pentoxifylline—systemic scleroderma	0.000593	0.00311	CcSEcCtD
Canagliflozin—Hypoglycaemia—Mycophenolate mofetil—systemic scleroderma	0.000591	0.0031	CcSEcCtD
Canagliflozin—Skin disorder—Pentoxifylline—systemic scleroderma	0.000586	0.00307	CcSEcCtD
Canagliflozin—Pollakiuria—Mycophenolic acid—systemic scleroderma	0.000584	0.00306	CcSEcCtD
Canagliflozin—Angioedema—Mometasone—systemic scleroderma	0.000583	0.00305	CcSEcCtD
Canagliflozin—Urinary tract infection—Leflunomide—systemic scleroderma	0.000574	0.00301	CcSEcCtD
Canagliflozin—Hypotension—Pentoxifylline—systemic scleroderma	0.000564	0.00295	CcSEcCtD
Canagliflozin—Pancreatitis—Lisinopril—systemic scleroderma	0.000558	0.00292	CcSEcCtD
Canagliflozin—Urinary tract infection—Mycophenolic acid—systemic scleroderma	0.000548	0.00287	CcSEcCtD
Canagliflozin—Blood creatinine increased—Mycophenolate mofetil—systemic scleroderma	0.000541	0.00283	CcSEcCtD
Canagliflozin—Dehydration—Mycophenolate mofetil—systemic scleroderma	0.000537	0.00281	CcSEcCtD
Canagliflozin—Dry mouth—Mometasone—systemic scleroderma	0.000531	0.00278	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Mycophenolate mofetil—systemic scleroderma	0.000527	0.00276	CcSEcCtD
Canagliflozin—Urinary tract disorder—Leflunomide—systemic scleroderma	0.000524	0.00274	CcSEcCtD
Canagliflozin—Urethral disorder—Leflunomide—systemic scleroderma	0.00052	0.00272	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Lisinopril—systemic scleroderma	0.00052	0.00272	CcSEcCtD
Canagliflozin—Infection—Mometasone—systemic scleroderma	0.000517	0.00271	CcSEcCtD
Canagliflozin—Constipation—Pentoxifylline—systemic scleroderma	0.000516	0.0027	CcSEcCtD
Canagliflozin—Angioedema—Captopril—systemic scleroderma	0.000512	0.00268	CcSEcCtD
Canagliflozin—Syncope—Captopril—systemic scleroderma	0.000502	0.00263	CcSEcCtD
Canagliflozin—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.0005	0.00262	CcSEcCtD
Canagliflozin—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.000496	0.0026	CcSEcCtD
Canagliflozin—Urinary tract infection—Lisinopril—systemic scleroderma	0.000493	0.00258	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.000493	0.00258	CcSEcCtD
Canagliflozin—Loss of consciousness—Captopril—systemic scleroderma	0.000492	0.00258	CcSEcCtD
Canagliflozin—Pancreatitis—Mycophenolate mofetil—systemic scleroderma	0.000489	0.00256	CcSEcCtD
Canagliflozin—Urticaria—Pentoxifylline—systemic scleroderma	0.000479	0.00251	CcSEcCtD
Canagliflozin—Abdominal pain—Pentoxifylline—systemic scleroderma	0.000477	0.0025	CcSEcCtD
Canagliflozin—Dry mouth—Captopril—systemic scleroderma	0.000466	0.00244	CcSEcCtD
Canagliflozin—Malnutrition—Leflunomide—systemic scleroderma	0.000462	0.00242	CcSEcCtD
Canagliflozin—Pollakiuria—Mycophenolate mofetil—systemic scleroderma	0.000461	0.00241	CcSEcCtD
Canagliflozin—Angiopathy—Mycophenolic acid—systemic scleroderma	0.000459	0.0024	CcSEcCtD
Canagliflozin—Urinary tract disorder—Lisinopril—systemic scleroderma	0.00045	0.00236	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisone—systemic scleroderma	0.00045	0.00235	CcSEcCtD
Canagliflozin—Shock—Captopril—systemic scleroderma	0.00045	0.00235	CcSEcCtD
Canagliflozin—Fatigue—Mometasone—systemic scleroderma	0.000449	0.00235	CcSEcCtD
Canagliflozin—Urethral disorder—Lisinopril—systemic scleroderma	0.000447	0.00234	CcSEcCtD
Canagliflozin—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000444	0.00233	CcSEcCtD
Canagliflozin—Malnutrition—Mycophenolic acid—systemic scleroderma	0.00044	0.00231	CcSEcCtD
Canagliflozin—Cystitis noninfective—Methotrexate—systemic scleroderma	0.00044	0.0023	CcSEcCtD
Canagliflozin—Cystitis—Methotrexate—systemic scleroderma	0.000435	0.00228	CcSEcCtD
Canagliflozin—Asthenia—Pentoxifylline—systemic scleroderma	0.000433	0.00227	CcSEcCtD
Canagliflozin—Urinary tract infection—Mycophenolate mofetil—systemic scleroderma	0.000432	0.00226	CcSEcCtD
Canagliflozin—Hypotension—Captopril—systemic scleroderma	0.000427	0.00224	CcSEcCtD
Canagliflozin—Pruritus—Pentoxifylline—systemic scleroderma	0.000427	0.00223	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000426	0.00223	CcSEcCtD
Canagliflozin—Vaginal infection—Methotrexate—systemic scleroderma	0.000425	0.00223	CcSEcCtD
Canagliflozin—Angioedema—Leflunomide—systemic scleroderma	0.000422	0.00221	CcSEcCtD
Canagliflozin—Angiopathy—Lisinopril—systemic scleroderma	0.000413	0.00216	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000413	0.00216	CcSEcCtD
Canagliflozin—Abdominal pain—Mometasone—systemic scleroderma	0.000411	0.00215	CcSEcCtD
Canagliflozin—Urine output increased—Methotrexate—systemic scleroderma	0.000407	0.00213	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—systemic scleroderma	0.000407	0.00213	CcSEcCtD
Canagliflozin—Dizziness—Pentoxifylline—systemic scleroderma	0.000399	0.00209	CcSEcCtD
Canagliflozin—Erythema—Lisinopril—systemic scleroderma	0.000397	0.00208	CcSEcCtD
Canagliflozin—Malnutrition—Lisinopril—systemic scleroderma	0.000397	0.00208	CcSEcCtD
Canagliflozin—Infection—Azathioprine—systemic scleroderma	0.000396	0.00208	CcSEcCtD
Canagliflozin—Syncope—Mycophenolic acid—systemic scleroderma	0.000395	0.00207	CcSEcCtD
Canagliflozin—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000394	0.00206	CcSEcCtD
Canagliflozin—Fatigue—Captopril—systemic scleroderma	0.000394	0.00206	CcSEcCtD
Canagliflozin—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000391	0.00205	CcSEcCtD
Canagliflozin—Constipation—Captopril—systemic scleroderma	0.000391	0.00205	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00039	0.00204	CcSEcCtD
Canagliflozin—Skin disorder—Azathioprine—systemic scleroderma	0.000387	0.00203	CcSEcCtD
Canagliflozin—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.000387	0.00203	CcSEcCtD
Canagliflozin—Dry mouth—Leflunomide—systemic scleroderma	0.000384	0.00201	CcSEcCtD
Canagliflozin—Convulsion—Mycophenolic acid—systemic scleroderma	0.000382	0.002	CcSEcCtD
Canagliflozin—Rash—Pentoxifylline—systemic scleroderma	0.00038	0.00199	CcSEcCtD
Canagliflozin—Dermatitis—Pentoxifylline—systemic scleroderma	0.00038	0.00199	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—systemic scleroderma	0.000376	0.00197	CcSEcCtD
Canagliflozin—Infection—Leflunomide—systemic scleroderma	0.000374	0.00196	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Captopril—systemic scleroderma	0.000374	0.00196	CcSEcCtD
Canagliflozin—Asthenia—Mometasone—systemic scleroderma	0.000373	0.00196	CcSEcCtD
Canagliflozin—Hypotension—Azathioprine—systemic scleroderma	0.000373	0.00195	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000372	0.00195	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—systemic scleroderma	0.000372	0.00195	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—systemic scleroderma	0.000372	0.00195	CcSEcCtD
Canagliflozin—Nervous system disorder—Leflunomide—systemic scleroderma	0.000369	0.00193	CcSEcCtD
Canagliflozin—Pruritus—Mometasone—systemic scleroderma	0.000368	0.00193	CcSEcCtD
Canagliflozin—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000367	0.00192	CcSEcCtD
Canagliflozin—Skin disorder—Leflunomide—systemic scleroderma	0.000366	0.00192	CcSEcCtD
Canagliflozin—Angioedema—Lisinopril—systemic scleroderma	0.000362	0.0019	CcSEcCtD
Canagliflozin—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000362	0.0019	CcSEcCtD
Canagliflozin—Abdominal pain—Captopril—systemic scleroderma	0.000361	0.00189	CcSEcCtD
Canagliflozin—Nausea—Pentoxifylline—systemic scleroderma	0.000358	0.00188	CcSEcCtD
Canagliflozin—Infection—Mycophenolic acid—systemic scleroderma	0.000357	0.00187	CcSEcCtD
Canagliflozin—Syncope—Lisinopril—systemic scleroderma	0.000356	0.00186	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—systemic scleroderma	0.000354	0.00185	CcSEcCtD
Canagliflozin—Shock—Mycophenolic acid—systemic scleroderma	0.000354	0.00185	CcSEcCtD
Canagliflozin—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000352	0.00185	CcSEcCtD
Canagliflozin—Hypotension—Leflunomide—systemic scleroderma	0.000352	0.00184	CcSEcCtD
Canagliflozin—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000349	0.00183	CcSEcCtD
Canagliflozin—Loss of consciousness—Lisinopril—systemic scleroderma	0.000349	0.00183	CcSEcCtD
Canagliflozin—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000348	0.00182	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000344	0.0018	CcSEcCtD
Canagliflozin—Hypotension—Mycophenolic acid—systemic scleroderma	0.000336	0.00176	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000335	0.00176	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisone—systemic scleroderma	0.000331	0.00174	CcSEcCtD
Canagliflozin—Dry mouth—Lisinopril—systemic scleroderma	0.00033	0.00173	CcSEcCtD
Canagliflozin—Rash—Mometasone—systemic scleroderma	0.000328	0.00172	CcSEcCtD
Canagliflozin—Asthenia—Captopril—systemic scleroderma	0.000328	0.00172	CcSEcCtD
Canagliflozin—Dermatitis—Mometasone—systemic scleroderma	0.000328	0.00172	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000326	0.00171	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000325	0.0017	CcSEcCtD
Canagliflozin—Fatigue—Leflunomide—systemic scleroderma	0.000325	0.0017	CcSEcCtD
Canagliflozin—Pruritus—Captopril—systemic scleroderma	0.000323	0.00169	CcSEcCtD
Canagliflozin—Constipation—Leflunomide—systemic scleroderma	0.000322	0.00169	CcSEcCtD
Canagliflozin—Infection—Lisinopril—systemic scleroderma	0.000322	0.00168	CcSEcCtD
Canagliflozin—Shock—Lisinopril—systemic scleroderma	0.000318	0.00167	CcSEcCtD
Canagliflozin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000318	0.00166	CcSEcCtD
Canagliflozin—Abdominal pain—Azathioprine—systemic scleroderma	0.000315	0.00165	CcSEcCtD
Canagliflozin—Skin disorder—Lisinopril—systemic scleroderma	0.000314	0.00165	CcSEcCtD
Canagliflozin—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000312	0.00163	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00031	0.00162	CcSEcCtD
Canagliflozin—Fatigue—Mycophenolic acid—systemic scleroderma	0.00031	0.00162	CcSEcCtD
Canagliflozin—Nausea—Mometasone—systemic scleroderma	0.000309	0.00162	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000308	0.00161	CcSEcCtD
Canagliflozin—Constipation—Mycophenolic acid—systemic scleroderma	0.000307	0.00161	CcSEcCtD
Canagliflozin—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000305	0.0016	CcSEcCtD
Canagliflozin—Hypotension—Lisinopril—systemic scleroderma	0.000302	0.00158	CcSEcCtD
Canagliflozin—Dizziness—Captopril—systemic scleroderma	0.000302	0.00158	CcSEcCtD
Canagliflozin—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000301	0.00158	CcSEcCtD
Canagliflozin—Urticaria—Leflunomide—systemic scleroderma	0.000299	0.00157	CcSEcCtD
Canagliflozin—Abdominal pain—Leflunomide—systemic scleroderma	0.000298	0.00156	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—systemic scleroderma	0.000295	0.00155	CcSEcCtD
Canagliflozin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000294	0.00154	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000294	0.00154	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000294	0.00154	CcSEcCtD
Canagliflozin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000289	0.00152	CcSEcCtD
Canagliflozin—Rash—Captopril—systemic scleroderma	0.000288	0.00151	CcSEcCtD
Canagliflozin—Dermatitis—Captopril—systemic scleroderma	0.000288	0.00151	CcSEcCtD
Canagliflozin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000284	0.00149	CcSEcCtD
Canagliflozin—Infection—Mycophenolate mofetil—systemic scleroderma	0.000282	0.00148	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000279	0.00146	CcSEcCtD
Canagliflozin—Fatigue—Lisinopril—systemic scleroderma	0.000279	0.00146	CcSEcCtD
Canagliflozin—Shock—Mycophenolate mofetil—systemic scleroderma	0.000279	0.00146	CcSEcCtD
Canagliflozin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000278	0.00146	CcSEcCtD
Canagliflozin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000278	0.00145	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—systemic scleroderma	0.000277	0.00145	CcSEcCtD
Canagliflozin—Constipation—Lisinopril—systemic scleroderma	0.000277	0.00145	CcSEcCtD
Canagliflozin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000275	0.00144	CcSEcCtD
Canagliflozin—Nausea—Captopril—systemic scleroderma	0.000272	0.00142	CcSEcCtD
Canagliflozin—Asthenia—Leflunomide—systemic scleroderma	0.00027	0.00142	CcSEcCtD
Canagliflozin—Pruritus—Leflunomide—systemic scleroderma	0.000267	0.0014	CcSEcCtD
Canagliflozin—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000265	0.00139	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000265	0.00139	CcSEcCtD
Canagliflozin—Dizziness—Azathioprine—systemic scleroderma	0.000264	0.00138	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000258	0.00135	CcSEcCtD
Canagliflozin—Asthenia—Mycophenolic acid—systemic scleroderma	0.000258	0.00135	CcSEcCtD
Canagliflozin—Urticaria—Lisinopril—systemic scleroderma	0.000257	0.00135	CcSEcCtD
Canagliflozin—Abdominal pain—Lisinopril—systemic scleroderma	0.000256	0.00134	CcSEcCtD
Canagliflozin—Pruritus—Mycophenolic acid—systemic scleroderma	0.000254	0.00133	CcSEcCtD
Canagliflozin—Rash—Azathioprine—systemic scleroderma	0.000252	0.00132	CcSEcCtD
Canagliflozin—Dermatitis—Azathioprine—systemic scleroderma	0.000251	0.00132	CcSEcCtD
Canagliflozin—Dizziness—Leflunomide—systemic scleroderma	0.000249	0.0013	CcSEcCtD
Canagliflozin—Angiopathy—Prednisone—systemic scleroderma	0.000246	0.00129	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000245	0.00128	CcSEcCtD
Canagliflozin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000243	0.00127	CcSEcCtD
Canagliflozin—Hypersensitivity—Lisinopril—systemic scleroderma	0.000238	0.00125	CcSEcCtD
Canagliflozin—Dizziness—Mycophenolic acid—systemic scleroderma	0.000238	0.00124	CcSEcCtD
Canagliflozin—Rash—Leflunomide—systemic scleroderma	0.000238	0.00124	CcSEcCtD
Canagliflozin—Dermatitis—Leflunomide—systemic scleroderma	0.000237	0.00124	CcSEcCtD
Canagliflozin—Nausea—Azathioprine—systemic scleroderma	0.000237	0.00124	CcSEcCtD
Canagliflozin—Erythema—Prednisone—systemic scleroderma	0.000236	0.00123	CcSEcCtD
Canagliflozin—Malnutrition—Prednisone—systemic scleroderma	0.000236	0.00123	CcSEcCtD
Canagliflozin—Asthenia—Lisinopril—systemic scleroderma	0.000232	0.00122	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000232	0.00121	CcSEcCtD
Canagliflozin—Pruritus—Lisinopril—systemic scleroderma	0.000229	0.0012	CcSEcCtD
Canagliflozin—Rash—Mycophenolic acid—systemic scleroderma	0.000227	0.00119	CcSEcCtD
Canagliflozin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000226	0.00119	CcSEcCtD
Canagliflozin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000225	0.00118	CcSEcCtD
Canagliflozin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000224	0.00117	CcSEcCtD
Canagliflozin—Nausea—Leflunomide—systemic scleroderma	0.000224	0.00117	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000223	0.00117	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—systemic scleroderma	0.000222	0.00116	CcSEcCtD
Canagliflozin—Angioedema—Prednisone—systemic scleroderma	0.000215	0.00113	CcSEcCtD
Canagliflozin—Dizziness—Lisinopril—systemic scleroderma	0.000214	0.00112	CcSEcCtD
Canagliflozin—Nausea—Mycophenolic acid—systemic scleroderma	0.000213	0.00112	CcSEcCtD
Canagliflozin—Syncope—Prednisone—systemic scleroderma	0.000211	0.00111	CcSEcCtD
Canagliflozin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000209	0.00109	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisone—systemic scleroderma	0.000207	0.00108	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—systemic scleroderma	0.000205	0.00107	CcSEcCtD
Canagliflozin—Rash—Lisinopril—systemic scleroderma	0.000204	0.00107	CcSEcCtD
Canagliflozin—Convulsion—Prednisone—systemic scleroderma	0.000204	0.00107	CcSEcCtD
Canagliflozin—Dermatitis—Lisinopril—systemic scleroderma	0.000204	0.00107	CcSEcCtD
Canagliflozin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000203	0.00107	CcSEcCtD
Canagliflozin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000201	0.00105	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000199	0.00104	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—systemic scleroderma	0.000197	0.00103	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—systemic scleroderma	0.000197	0.00103	CcSEcCtD
Canagliflozin—Nausea—Lisinopril—systemic scleroderma	0.000192	0.00101	CcSEcCtD
Canagliflozin—Infection—Prednisone—systemic scleroderma	0.000191	0.001	CcSEcCtD
Canagliflozin—Shock—Prednisone—systemic scleroderma	0.000189	0.00099	CcSEcCtD
Canagliflozin—Nervous system disorder—Prednisone—systemic scleroderma	0.000189	0.000987	CcSEcCtD
Canagliflozin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000188	0.000982	CcSEcCtD
Canagliflozin—Skin disorder—Prednisone—systemic scleroderma	0.000187	0.000978	CcSEcCtD
Canagliflozin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000936	CcSEcCtD
Canagliflozin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000936	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—systemic scleroderma	0.000171	0.000893	CcSEcCtD
Canagliflozin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000882	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000166	0.000872	CcSEcCtD
Canagliflozin—Fatigue—Prednisone—systemic scleroderma	0.000166	0.000868	CcSEcCtD
Canagliflozin—Constipation—Prednisone—systemic scleroderma	0.000164	0.000861	CcSEcCtD
Canagliflozin—Infection—Methotrexate—systemic scleroderma	0.00016	0.000836	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—systemic scleroderma	0.000158	0.000825	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000157	0.000823	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—systemic scleroderma	0.000156	0.000817	CcSEcCtD
Canagliflozin—Urticaria—Prednisone—systemic scleroderma	0.000153	0.0008	CcSEcCtD
Canagliflozin—Abdominal pain—Prednisone—systemic scleroderma	0.000152	0.000796	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—systemic scleroderma	0.00015	0.000786	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisone—systemic scleroderma	0.000142	0.000742	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000139	0.000726	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—systemic scleroderma	0.000139	0.000725	CcSEcCtD
Canagliflozin—Asthenia—Prednisone—systemic scleroderma	0.000138	0.000722	CcSEcCtD
Canagliflozin—Pruritus—Prednisone—systemic scleroderma	0.000136	0.000712	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000131	0.000688	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—systemic scleroderma	0.000128	0.000668	CcSEcCtD
Canagliflozin—Dizziness—Prednisone—systemic scleroderma	0.000127	0.000666	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—systemic scleroderma	0.000127	0.000665	CcSEcCtD
Canagliflozin—Rash—Prednisone—systemic scleroderma	0.000121	0.000635	CcSEcCtD
Canagliflozin—Dermatitis—Prednisone—systemic scleroderma	0.000121	0.000634	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—systemic scleroderma	0.000118	0.00062	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—systemic scleroderma	0.000115	0.000604	CcSEcCtD
Canagliflozin—Nausea—Prednisone—systemic scleroderma	0.000114	0.000598	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—systemic scleroderma	0.000114	0.000595	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—systemic scleroderma	0.000106	0.000556	CcSEcCtD
Canagliflozin—Rash—Methotrexate—systemic scleroderma	0.000101	0.00053	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—systemic scleroderma	0.000101	0.00053	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—systemic scleroderma	9.54e-05	0.0005	CcSEcCtD
